Jazz Pharmaceuticals (JAZZ) return on equity (ROE)

Return on equity · fiscal 2025
-8.2%

Jazz Pharmaceuticals (JAZZ) earned a return on equity of -8.2% in fiscal 2025 (the year ended December 31, 2025). That is 21.9 percentage points lower than the 13.7% of fiscal 2024. Figures as of 17 Nov 2026, 23:19 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Return on equity, fiscal 2025
-8.2%
Change on fiscal 2024
−21.9 pts
Highest on record
107.3%fiscal 2010
Lowest on record
-8.3%fiscal 2021
Fiscal years on record
162010–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Figures, not advice.

Jazz Pharmaceuticals return on equity (ROE), in more detail

Across the 16 fiscal years on record (2010–2025), the highest was 107.3% in fiscal 2010 and the lowest -8.3% in fiscal 2021. The fiscal 2025 figure is higher than in 7% of the 15 earlier fiscal years on record, whose median is 16.7%.

History · 16 fiscal years

Return on equity by fiscal year

Jazz Pharmaceuticals return on equity (ROE), year by year

Jazz Pharmaceuticals (JAZZ) return on equity (ROE) by fiscal year
Fiscal yearReturn on equityChangeYear ended
2025-8.2% 21.9 pts down
202413.7% 2.6 pts up
202311.1% 18.4 pts up
2022-7.3% 1.1 pts up
2021-8.3% 14.8 pts down
20206.5% 10.3 pts down
201916.8% 0.6 pts up
201816.2% 1.8 pts down
201718.0% 3.2 pts down
201621.1% 0.5 pts up
201520.6% 16.4 pts up
20144.3% 12.4 pts down
201316.7% 9.0 pts down
201225.7% 39.1 pts down
201164.8% 42.5 pts down
2010107.3%—

Change is on the fiscal year before, in percentage points; a dash means that year is not on record. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

How to read it

It is the profit earned on the owners' capital — above about 15% is strong, though heavy debt or large buybacks can inflate it.

Return on equity at health care companies of similar size

Return on equity of Jazz Pharmaceuticals and comparable companies
CompanyReturn on equityFiscal year
Neurocrine Biosciences NBIX14.7%2025
Ascendis Pharma ASND-221.5%2022
ICON ICLR2.5%2025
Jazz Pharmaceuticals JAZZ-8.2%2025
Solventum SOLV30.8%2025
BridgeBio Pharma BBIO-872.9%2020

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on JAZZ

Jazz Pharmaceuticals, figure by figure

Jazz Pharmaceuticals (JAZZ) overview: price, valuation and scorecardAll health care companies by market value

Jazz Pharmaceuticals return on equity (ROE): questions and answers

What is Jazz Pharmaceuticals's return on equity?

Jazz Pharmaceuticals (JAZZ) earned a return on equity of -8.2% in fiscal 2025 (the year ended December 31, 2025). That is 21.9 percentage points lower than the 13.7% of fiscal 2024.

Is Jazz Pharmaceuticals's return on equity high or low compared with its own history?

The fiscal 2025 figure is higher than in 7% of the 15 earlier fiscal years on record, whose median is 16.7%.

What are the highest and lowest return on equity figures on record for Jazz Pharmaceuticals?

Across the 16 fiscal years on record (2010–2025), the highest was 107.3% in fiscal 2010 and the lowest -8.3% in fiscal 2021.

How is Jazz Pharmaceuticals's return on equity calculated?

Return on equity is net income divided by shareholders' equity at the fiscal year-end; it is left blank when equity is negative.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Jazz Pharmaceuticals (JAZZ) return on equity (ROE)”, data as of 17 November 2026. https://funkfolio.com/stock/JAZZ/roe

Underlying data: the company's filings with the SEC and Yahoo Finance.